Arabic Arabic English English French French German German
dark

Thetis Pharmaceuticals Launches Resolvin E1 Cancer Program and Scientific Advisory Board

Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company developing Resolvin-based therapies, announced today the launch of a new program in cancer and the formation of a scientific advisory board (SAB) with several prominent cancer researchers and industry veterans. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

AiCuris Starts Its First Pivotal Clinical Phase 3 Trial with Pritelivir for the Treatment of HSV Infections in Immunocompromised Subjects Based on Efficacy and Safety Data from a Phase 2 Trial

Next Post

Xeltis Initiates First-ever Pivotal Trial of a Synthetic Restorative Pulmonary Heart Valve

Related Posts
Total
0
Share